Clinical Phototoxicity and Photogenotoxicity Studies
We administer new drugs and medications to paid volunteers who are randomised. Patients are
randomised to receive either drug or placebo or positive
control. Small areas of the skin are exposed to specific quantities of light.
Skin reactions are assessed and compared with baseline levels. Studies involve
systemic or topical agents.
Certain drugs (and other chemicals) that penetrate the skin
may cause reactions that occur only when the skin is exposed
to light. This is a result of interactions between photons
of light and the chemical within the skin. Substances that
cause such reactions are usually phototoxic in mechanism.
The skin manifestations of phototoxicity vary and include
swelling, redness, blistering and pigmentation. Phototoxicity
is not immunologically based and can arise in anyone provided
there is enough of the drug and appropriate radiation. Because
this has become increasingly important to patients, regulatory
authorities and the pharmaceutical industry, photosafety regulatory guidelines
were introduced earlier this decade both in Europe and in the USA. Individual
drug issues are assessed on a case by case basis with significant
flexibility about which laboratory and clinical studies are considered necessary.
In
detail, our services comprise:
- Volunteer phototoxicity studies for topical and systemic
drugs
- Laboratory phototoxicity and photogenotoxicity
testing
- Study design
- Protocol production and review (in collaboration
with sponsor)
- Ethics submission and approval
- Obtaining Regulatory approval (if necessary)
- CRF or eCRF (case report
form) design
- IMP (investigational medicinal product)
management
- Volunteer recruitment and consent
- Dosing and sampling
- Data management and recording of results
- Monitoring and Quality Assurance
- Interpretation of results, report
writing and advice on product labelling and clinical
management
- Accident and Emergency management
|